The individualized treatment of type 2 diabetes mellitus, using various glucagon-like peptide receptor agonists (GLP1RAs), has recently been described. As experience with existing GLP1RAs grows, and as newer molecules in the development pipeline continue to progress, interest related to these drugs continues to grow. This article describes a person-centered approach, using the bio-psychosocial model of health, to help individualized decision making related to choice of GLP1RA. It utilizes an evidence-based approach to discuss various biomedical and psychosocial factors which may influence choice of GLP1RA.
Short-acting GLP1RAs are those with a half-life of \12 h, which requires daily or twice daily administration [2, 3] . Intermediate-acting GLP1RAs are those with a half-life of [12 h [4] , which allow once daily injection. Long-acting
GLP1RAs have half-lives of [24 h [5, 6] and can be injected as once-weekly doses. The oncedaily GLP1RA, viz, liraglutide and lixisenatide, are also being developed as fixed ratio coformulations with basal insulins, viz, degludec and glargine, respectively.
PROTRACTION OF DURATION OF ACTION
Various GLP1RAs have been utilizing differing strategies to prolong or protract their duration of action. The shortest-acting GLP1RA, viz exenatide and lixisenatide [3, 7] , achieve this by exchanging amino acids at the N2 and N3
positions, thus making them resistant to breakdown by dipeptidyl peptidase 4 (DPP4). The renal elimination of the molecule, however, continues as per physiology, and so drug levels fall to baseline prior to the next injection. The short half-life of 2-4 h means that peak concentrations are maintained for just 6 h.
Liraglutide achieves a longer half-life (12-13 h) and duration of action, by having a fatty acid side chain. This allows it to bind noncovalently to plasma albumin. This increases its size and slows down release of the GLP 1 moiety from plasma albumin, thus prolonging its action [8] . Albiglutide uses a similar albuminbinding based approach, but binds in a covalent manner to the protein. The long half-life of the albumin-GLP1 conjugate allows for a long duration of action and once-weekly administration [5, 9] . Dulaglutide employs a novel mechanism of protraction of action. It conjugates GLP-1 with the Fc fragment of IgG and thus achieves a longer duration of action [10, 11] . Exenatide long-acting release (LAR) is a chemical modification of exenatide, which is coupled to microspheres that allow slow and steady release of the molecule from its subcutaneous site [6] .
PATIENT-CENTERED PHILOSOPHY
Current guidelines promote a patient-centered approach to the management of diabetes. In essence, a patient-centered approach implies crafting of a management strategy which involves the patient and is respectful of his or her opinion. Viewed through a larger prism, patient-centered care assumes acceptance of the bio-psychosocial model of disease. It is understood that biomedical, psychological, and 
FACTORS INFLUENCING CHOICE OF GLP1RA
Various factors which influence the choice of a GLP1RA can be categorized according to the bio-psychosocial model (Table 2) .
BIOMEDICAL FACTORS
The biomedical factors which inform the appropriate choice of GLP1RA include efficacy, Efficacy is an important determinant choice. The shorter-acting GLP1RAs have a greater effect on postprandial glycemia, while the longer-acting molecules lower fasting glucose to a greater extent. Short-acting GLP1RAs delay gastric emptying, decrease the rate of glucose delivery to the duodenum, blunt postprandial glycemia excursions, and reduce insulin levels as well. They also help in reducing postprandial lipid levels. However, their short duration of action means that optimal glucose control may not be achieved over the full 24 h [12] .
Exenatide lowers breakfast and post-dinner glucose levels to a much greater degree than post-lunch excursions. This is expected with a twice-daily dose, keeping its pharmacokinetic profile in mind. The HbA1c reduction varies from 0.8% to 1.5% with the recommended dose of 10 lg twice daily [13] [14] [15] [16] . Gastrointestinal effects and hypoglycemia are less common than with exenatide; liraglutide also exhibits added benefits of low antibody formation, reduction in systolic blood pressure, and greater weight loss [24] . The drug is associated with a slight increase in pulse rate, and the impact of this positive chronotropic effect on cardiovascular health is uncertain.
Intermediate-and long-acting GLP1RAs exhibit greater effect on fasting glucose levels, as they continue to act during the nighttime.
They do not have a significant effect on gastric motility, as the initial slowing is abolished due to tachyphylaxis. Shorter-acting GLP1RAs do not suffer from tachyphylaxis because of their intermittent action [3] .
The Nausea and a positive chronotropic effect are noted with this long-acting GLP1RA.
Injection site reactions such as nodule formation are most often observed with exenatide LAR, which also needs thicker gauge needle for administration [29] [30] [31] [32] . While diarrhea occurs more frequently with longer- 
PSYCHOSOCIAL FACTORS
Psychosocial factors may also influence the choice of a GLP1RA. The ability of the patient to self-inject, to adhere to pre-specified times of injection(30 min before meals for exenatide), manual dexterity, frequency of contact with health-care providers, meal pattern followed, and adherence to therapy are some of these issues. sitagliptin is not significant [36] . No difference was perceived in the convenience of treatment between the oral versus injectable. Compared to patients on traditional therapy which was insulin, patients taking exenatide showed greater satisfaction, increased well-being and decreased anxiety [37] . Liraglutide 1.8 mg versus glimepiride improves psychological and emotional well-being and health perceptions by reducing anxiety and worry associated with weight gain [38] .
CONCLUSION
The preceding discussion provides a reasonably robust evidence-based assessment upon which an appropriate GLP1RA can be chosen or changed. Further research and experience will help utilize GLP1RA therapy in the best possible manner for the benefit of people with diabetes.
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